Importer of Controlled Substances Application: Fisher Clinical Services, Inc.
Published Date: 11/26/2025
Notice
Summary
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and its extracts. This affects companies involved in drug manufacturing and importation, who can comment or request a hearing by December 26, 2025. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
No Commercial Finished Dosage Imports Allowed
The registration, if approved, will not authorize importation of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale; approval is limited to activities consistent with 21 U.S.C. 952(a)(2).
Deadline to Comment or Request Hearing
If you are a registered bulk manufacturer or an applicant, you may submit electronic comments or objections, or file a written request for a hearing, by December 26, 2025. Comments must be submitted through https://www.regulations.gov and hearing requests must also be mailed to the Drug Enforcement Administration addresses listed in the notice.
Application to Import Specific Controlled Substances
Fisher Clinical Services, Inc. applied on August 26, 2025 to be registered to import specific Schedule I and II substances — including marihuana, marihuana extract, tetrahydrocannabinols, 5‑MeO‑DMT, DMT, psilocybin, methylphenidate, levorphanol, noroxymorphone, and tapentadol — and says it plans to import them for use in clinical trials only.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Previous / Next Documents
Previous: 2025-21188 — Proposal Review; Notice of Meetings
The National Science Foundation (NSF) will hold closed meetings all year to review and decide on funding proposals for research projects. These meetings protect private info and won’t be open to the public, but you can check the NSF website for schedules and updates. This keeps the funding process fair and secure, with no direct cost changes announced.
Next: 2025-21190 — Bulk Manufacturer of Controlled Substances Application: National Center for Natural Products Research
The National Center for Natural Products Research wants to officially make large amounts of marijuana and related substances for research and product development. If you’re a current manufacturer or interested party, you can share your thoughts or ask for a hearing by January 26, 2026. This move could boost scientific studies and product testing, with no immediate cost changes announced.